References
- Yeni PG, Hammer SM, Carpenter CC etal Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAIVI410, 222–235 (2002).
- ••Treatment guidelines for treatment ofpeople infected with HIV-1.
- Dybul M, Fauci AS, Bartlett JG etal Panel on Clinical Practices for Treatment of HIV Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 137, 381–433 (2002).
- ••Treatment recent guidelines for treatmentof people infected with HIV-1.
- Bartholomew C. Prices of CD4 assays and viral load tests must be reduced for developing countries. BE Med. J. 323,809-810 (2001).
- •Letter illuminating the high cost of diagnostic tests in developing countries.
- Rabkin M, El-Sadr W, Katzenstein DA etal Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet360, 1503–1505 (2002).
- ••Suggests treatment guidelines forresource-poor countries.
- Hirschel B. Antiretroviral treatment and research in resource-poor countries. Lancet 361, 434–435 (2003).
- Stephenson J. Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment. JAIVIA 288, 151–153 (2002).
- Schupbach J. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Rev 4, 83–92 (2002).
- ••Shows significant development in HIV-1P24 antigen assay for the monitoring of HIV–1.
- Sutthent R, Gaudart N, Chokpaibulkit K etal p24 Antigen Detection Assay Modified with a Booster Step for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection. J. Cita. Mcrobial 41, 1016–1022 (2003).
- Braun J, Plantier JC, Hellot ME etal A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS14, 331–336 (2003).
- Vergne L, Malonga-Mouellet G, Mistoul I etal Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J. Acquit: Immune. Defic. Syndr. 29, 165–168 (2002).
- Adje C, Cheingsong R, Roels TH eta]. The UNAIDS HIV Drug Access Initiative, Abidjan, Cote d'Ivoire. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. I Acquit: Immune. Defic. Synth: 26, 501–506 (2001).
- Gleaves CA, Welle J, Campbell M etal Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J. Gun. Viral 25,205–16 (2002).
- Triques K, Coste J, Perret JL etal Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus Type 1.1 Gun. Nliavbial 37, 110–116 (1999).
- Elbeik T, Charlebois E, Nassos P et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus Type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5.1 Gun. Microbial. 38, 1113–1120 (2000).
- ••First comparative cost analysis used todevelop the models described.
- Elbeik T, Loftus RA, Beringer S. Healthcare industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Rev. Mal Diagn. 2, 275–285 (2002).
- •Describes of the strengths and weaknesses of Bayer and Roche HIV-1 assays.